Teplyakov A T, Sankevitch T V, Stepatcheva T A, Mamchur S E
Research Institute for Cardiology of the Research Centre of RAMS Siberian Branch; ul. Kievskaya 111, 634012 Tomsk, Russia.
Kardiologiia. 2003;43(12):15-8.
To assess antiischemic efficacy, safety and effect on myocardial perfusion of a course treatment with mildronate (as monotherapy and in combination with atenolol) in patients with postinfarction left ventricular dysfunction associated with moderate heart failure.
Patients (n=47) with postinfarction cardiosclerosis, angina, and decreased tolerance to physical exertion were divided into 2 groups. Patients of group 1 had functional class II angina and NYHA class I-II heart failure, patients of group 2 had functional class II-III angina and severe heart failure. Mildronate (0.75-1.0 g/day) was used as monotherapy in group 1 and in combination with atenolol (25-50 mg/day) in group 2. Duration of therapy was 3 weeks.
The use of mildronate was associated with marked antiischemic effect. Combined administration of mildronate and atenolol resulted in additional antiischemic effect without impairment of hemodynamics in patients with severe heart failure. Course use of mildronate was well tolerated. Adverse effects were registered in 4,2% of cases.
评估米屈膦酸盐（单一疗法以及与阿替洛尔联合使用）对伴有中度心力衰竭的心肌梗死后左心室功能不全患者进行一个疗程治疗时的抗缺血疗效、安全性及对心肌灌注的影响。
将患有心肌梗死后心肌硬化、心绞痛且体力活动耐量下降的患者（n = 47）分为2组。第1组患者为II级功能性心绞痛且纽约心脏协会（NYHA）心功能I-II级心力衰竭，第2组患者为II-III级功能性心绞痛且严重心力衰竭。第1组使用米屈膦酸盐（0.75 - 1.0克/天）作为单一疗法，第2组将米屈膦酸盐与阿替洛尔（25 - 50毫克/天）联合使用。治疗持续时间为3周。
使用米屈膦酸盐具有显著的抗缺血作用。米屈膦酸盐与阿替洛尔联合给药对严重心力衰竭患者产生了额外的抗缺血作用，且未损害血流动力学。米屈膦酸盐的疗程使用耐受性良好。4.2%的病例出现了不良反应。
